DIASORIN : SIGNS AN AGREEMENT WITH THE ITALIAN TAX AUTHORITY GRANTING TAX RELIEF UNDER THE ITALIAN PATENT BOX REGIME.

Press Release

DIASORIN SIGNS AN AGREEMENT WITH THE ITALIAN TAX AUTHORITY GRANTING TAX RELIEF UNDER

THE ITALIAN PATENT BOX REGIME.

Saluggia (Italy) - 30ThJanuary 2018 - DiaSorin S.p.A. (FTSE Italia: DIA) signed today an agreement with the Italian Tax Authority to access the Patent Box regime.

The Patent Box is an elective tax regime introduced by the Italian Government with the Stability Law of 2015, which grants a 50% exemption (reduced to 30% for 2015 and 40% for 2016) from corporate income tax, both IRES and IRAP, on income derived from direct exploitation of qualified IP (know how, trademarks and patents). The regime is characterized by a five-year lock-in period and the election is renewable.

The agreement signed today covers the period from 2015 to 2019 and provides DiaSorin an estimated tax benefit for the first three years in a range of about 16 ml to 18 ml euro.

According to Agenzia delle Entrate Circular n.11E dated 7 April 2016, such amount will be recovered into 2018 tax returns' submissions and will be reflected in the Group's 2017 financial statements. 2018 and 2019 tax benefits will be calculated and disclosed in the respective years Group's Annual Financial Statements.

Law References:

- Art 1 c. 37-45 law n.190 dated 23 December 2014 and following amendments;

- Economic Development Ministry decree dated 30 July 2015.

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the "Diagnostic Specialist".

For additional information, please contact: